Username Password
S&P 500: 2,061.23
Change: +2.40%
pspavento
P&P Score: 38.47 | Points: -1.26 | Accuracy: 28.57 | Average Pick Score: -68.64   Annual Return: N/A  
Open
 
Closed
 
All
 
Commentary
BUY: DENDREON CORPORATION (DNDN) Rating: 1
Start Price: $23.42
Points: -218.07
Created: 05/30/2009
Easy double or even triple.New prostate cancer drug has2-3 billion $ per year sales potential.Also company maybe takeover target for big pharma cos.

1 Comment(s):

Author pspavento     Date 2010-12-27 22:30:25
they will expanding indications for the drug to men who are NOT terminally ill. My target price for DNDN is $ 80=90 by teh end of 2011. Strong buy !!!
Want to comment on this post? Sign up now. It's FREE!
Already registered? Log In.

register
Sponsored Links